Immune checkpoint inhibitors in lung cancer: an update

References

• Kim R , EmiM, TanabeT. Cancer immunoediting from immune surveillance to immune escape. Immunology121(1), 1–14 (2007).
   PubMed Web of Science ®Google Scholar
• Seetharamu N , BudmanDR, SullivanKM. Immune checkpoint inhibitors in lung cancer: past, present and future. Future Oncol.12(9), 1151–1163 (2016).
   PubMed Web of Science ®Google Scholar
• NIC Staff . More Immunotherapy Options Approved for Lung Cancer.National Cancer Institute (2016). www.cancer.gov/news-events/cancer-currents-blog/2016/fda-atezolizumab-pembrolizumab-lung
   Google Scholar
• Brahmer J , ReckampKL, BaasPet al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med.373(2), 123–135 (2015).
   PubMed Web of Science ®Google Scholar
• Borghaei H , Paz-AresL, HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med.373(2), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Socinski M , CreelanB, HornLet al. CheckMate 026: a Phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann. Oncol.27(Suppl. 6), 582–587 (2016).
   Google Scholar
• Hellmann MD , ScottN, GettingerJWGet al. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J. Clin. Oncol.34(Suppl.), Abstract 3001 (2016).
   Google Scholar
• Herbst RS , BaasP, KimDWet al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet387(10027), 1540–1550 (2016).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodriguez-AbreuD, RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L , SpiraA, BallingerMet al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, Phase 2 randomised controlled trial. Lancet387(10030), 1837–1846 (2016).
   PubMed Web of Science ®Google Scholar
• Rittmeyer A , BarlesiF, WaterkampDet al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell-lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet389(10066), 255–265 (2016).
   PubMed Web of Science ®Google Scholar
• Antonia S , RizviN, BrahmerJet al. Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small-cell lung cancer (NSCLC). Cancer Immunol. Res.4(1), A047 (2016).
   Web of Science ®Google Scholar
• Planchard D , YokoiT, McCleodMJet al. A Phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin. Lung Cancer17(3), 232–236 (2016).
   PubMed Web of Science ®Google Scholar
• Gulley JL , SpigelD, KellyKet al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J. Clin. Oncol.33(Suppl.), Abstract 8034 (2015).
   Google Scholar
• Reck M , DeGreenHP, RoseHLet al. Avelumab (MSB0010718C; anti-PD-LI) vs platinum-based doublet as first-line treatment for metastatic or recurrent PDL1-positive non-small-cell lung cancer: the Phase 3 JAVELIN Lung 100 trial. J. Clin. Oncol.34(Suppl.), Abstract TPS9105 (2016).
   PubMedGoogle Scholar
• Tykodi SS , BrahmerJR, HwuW. PD-1/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J. Clin. Oncol.30(Suppl.), Abstract 2510 (2012).
   Google Scholar
• Ilie M , HofmanV, DietelM, SoriaJC, HofmanP. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch.468(5), 511–525 (2016).
   PubMed Web of Science ®Google Scholar
• Grigg C , RizviNA. PD-L1 biomarker testing for non-small-cell lung cancer: truth or fiction?J. Immunother. Cancer4, 48 (2016).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD, SnyderAet al. Mutational landscape determines sensitivity to PD-1 blockade in non-small-cell lung cancer. Science348(6230), 124–128 (2015).
   PubMed Web of Science ®Google Scholar
• Kowanetz M , ZouW, ShamesDSet al. Tumor mutational burden assessed by FoundationOne is associated with improved efficacy of atezolizumab in patients with advanced NSCLC. Presented at: ESMO Congress October 2016, Copenhagen, Denmark( Poster 77P).
   Google Scholar
• Yin M , YanJ, VoutsinaAet al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small-cell lung cancer: a meta-analysis. Lung Cancer72(3), 370–377 (2011).
   PubMed Web of Science ®Google Scholar
• Martinez De Castro A , NavarroA, Cedres PerezSet al. Lactate dehydrogenase (LDH) as a surrogate biomarker to checkpoint-inhibitors for patients with advanced non-small-cell lung cancer (NSCLC). Presented at: WCLC. Vienna, Austria, 3–7 December 2016 ( Poster 063).
   Google Scholar
• Aiello MM , Soto ParraHJ, NotoLet al. The role of ERCC-1 polymorphisms as predictive biomarker of response to nivolumab in advanced NSCLC. Presented at: WCLC. Vienna, Austria, 3–7 December 2016 ( Poster 6154).
   Google Scholar
• Muller M , VriesRD, SterkPet al. Electronic nose: an early response biomarker for anti-PD1 therapy in patients with NSCLC. Presented at: WCLC. Vienna, Austria, 3–7 December 2016 ( Poster 4528).
   Google Scholar
• Johnson DB , BalkoJM, ComptonMLet al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med.375(18), 1749–1755 (2016).
   PubMed Web of Science ®Google Scholar